News: Threshold Pharmaceuticals Inc (THLD.O)
THLD.O on Consolidated Issue listed on NASDAQ Capital Market
5.44USD
22 May 2013
5.44USD
22 May 2013
Price Change (% chg)
$-0.14 (-2.51%)
$-0.14 (-2.51%)
Prev Close
$5.58
$5.58
Open
$5.57
$5.57
Day's High
$5.74
$5.74
Day's Low
$5.25
$5.25
Volume
635,302
635,302
Avg. Vol
605,373
605,373
52-wk High
$9.28
$9.28
52-wk Low
$3.94
$3.94
Select another date:
Select another date:
Press Releases
- SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Threshold Pharmaceuticals Inc.
- Threshold Announces Acquisition of Investigational Hypoxia PET Imaging Agent [18F]HX4 From Siemens
- Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial and Operational Results
- Threshold Pharmaceuticals Announces Presentation and Webcast at Cowen and Company's 33rd Annual Health Care Conference
- Threshold Pharmaceuticals Announces Initiation of TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- Threshold Pharmaceuticals Announces Presentation and Webcast at Oppenheimer 23rd Annual Healthcare Conference
- Threshold Pharmaceuticals Reports Updated Phase 2 Results Including Analyses of Maintenance Therapy With TH-302 Following Induction Therapy With TH-302 Plus Doxorubicin in Soft Tissue Sarcoma
- Threshold Pharmaceuticals Announces Presentation and Webcast at Lazard Capital Markets 9th Annual Healthcare Conference
- Threshold Pharmaceuticals Reports Third Quarter 2012 Financial and Operational Results
- Threshold Pharmaceuticals Announces Agreement With U.S. FDA on a Special Protocol Assessment for Planned Phase 3 Trial of TH-302 in Combination With Gemcitabine in Advanced Pancreatic Cancer
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
